Post-earnings recap
Reported
Thu, May 6, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Nektar Therapeutics reported a wider-than-expected loss per share but did not disclose revenue figures. The stock reacted negatively, declining by 0.86%, likely due to the lack of revenue guidance and management's cautious tone regarding future prospects. Investors may be concerned about the company's ability to navigate current challenges without clear financial direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.68 | N/A | +5.16% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current market conditions affecting their operations. They emphasized their commitment to pipeline development.
Management did not provide specific revenue guidance for the upcoming quarters.
The focus remains on advancing their pipeline despite current challenges.